Systemic Exposure to Fluticasone Propionate Administered via Metered-Dose Inhaler Containing Chlorofluorocarbon or Hydrofluoroalkane Propellant

被引：0

作者：

Alison E. Mackie

Jo E. McDowall

Pietro Ventresca

Alan Bye

Christine Falcoz

Peter T. Daley-Yates

机构：

[1] Lilly Research Centre,Clinical Pharmacology

[2] Glaxo Wellcome Research and Development,undefined

[3] Glaxo Wellcome Research and Development,undefined

来源：

Clinical Pharmacokinetics | 2000年 / 39卷

关键词：

Fluticasone Propionate; Absolute Bioavailability; Chlorofluorocarbon; Urinary Cortisol; Urinary Cortisol Excretion;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：17 / 22

页数：5

共 50 条

[31] Metered-dose inhaler formulation of fluticasone-17-propionate micronized with supercritical carbon dioxide using the alternative propellant HFA-227
Steckel, H
Müller, BW
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 173 (1-2) : 25 - 33
[32] Systemic bioavailability (BA) and pharmacodynamics (PD) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) or a novel breath-triggered inhaler (BTI)
Bell, David
Mundin, Gill
Lomax, Mark
Woodward, Jo
Dalvi, Prashant
Dissanayake, Sanjeeva
EUROPEAN RESPIRATORY JOURNAL, 2017, 50
[33] Clinical Equivalence of a Salmeterol/Fluticasone Propionate Combination Product (50/500μg) Delivered via a Chlorofluorocarbon-Free Metered-Dose Inhaler with the Diskus™ in Patients with Moderate to Severe Asthma
J. A. van Noord
H. Lill
T. Carrillo Diaz
A. P. Greefhorst
P. Davies
Clinical Drug Investigation, 2001, 21 : 243 - 255
[34] Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered-Dose Inhaler
MacGregor, T. R.
ZuWallack, R.
Rubano, V.
Castles, M. A.
Dewberry, H.
Ghafouri, M.
Wood, C. C.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2016, 9 (02): : 105 - 113
[35] Switching from chlorofluorocarbon-beclomethasone dipropionate to a hydrofluoroalkane-134a beclomethasone dipropionate metered-dose inhaler: Study of patient preferences
Demedts, M
Cohen, RM
Cline, AC
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2000, 61 (03): : 120 - 126
[36] Systemic bioavailability of hydrofluoroalkane formulations containing fluticasone propionate and salmeterol
Daley-Yates, Peter T.
Parkins, David A.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (02) : 353 - 354
[37] THE SAFETY AND EFFICACY OF FLUTICASONE PROPIONATE 200-MU DAILY GIVEN VIA THE DISKHALER INHALER AS COMPARED WITH THE PRESSURIZED METERED-DOSE INHALER IN ADULT ASTHMA
DAHL, R
CLINICAL AND EXPERIMENTAL ALLERGY, 1993, 23 : 81 - 81
[38] Clinical equivalence of a salmeterol/fluticasone propionate combination product (50/500μg) delivered via a chlorofluorocarbon-free metered-dose inhaler with the Diskus™ in patients with moderate to severe asthma
van Noord, JA
Lill, H
Diaz, TC
Greefhorst, AP
Davies, P
CLINICAL DRUG INVESTIGATION, 2001, 21 (04) : 243 - 255
[39] Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma
Pinnas, JL
Noonan, MJ
Weinstein, SF
Chervinsky, P
Scott, CA
Herje, NE
Wu, W
Crim, C
JOURNAL OF ASTHMA, 2005, 42 (10) : 865 - 871
[40] Efficacy and Safety of Salmeterol/Fluticasone Propionate Combination Delivered by the Diskus™ or Pressurised Metered-Dose Inhaler in Children with Asthma
Teresa Bracamonte
Uwe Schauer
Andrzej Emeryk
Alex Godwood
Sima Balsara
Clinical Drug Investigation, 2005, 25 : 1 - 11

← 1 2 3 4 5 →